Back to results
US 12,753,203 B2Granted
Cyclin-dependent kinase inhibitors and methods of use
AssigneeDana-Farber Cancer Institute, Inc.
InventorsNathanael S. Gray, John Hatcher
Life of this patent
Estimating the term…
Abstract
Compounds of Formula (I) or pharmaceutically acceptable salts thereof are provided and methods involving compounds of Formula (I) as effective inhibitors of CDK8 and/or CDK19 are also provided.
Claims20
A compound represented by Formula (I):
- or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
- X is —OR, or —NR1R2;
- R is H or C1-C6 alkyl;
- R1 and R2 are each independently H, C1-C6 alkyl, —C(O)—C1-C6 alkyl, or R1 and R2, together with the nitrogen atom to which they are attached, form a 3- to 7-membered heterocyclic or a 5-, 8-, or 9-membered heteroaryl ring optionally comprising one or more additional heteroatoms selected from nitrogen, sulfur, and oxygen;
- u, v, and w together form (i):
- y and z together form (iv) or (v):
- Het is
- wherein a is CR3;
- b, c, and d are each independently CR3 or N, provided that at most two of b, c, and d are N;
- and each R3 is independently H or NH2,
- provided that Het is not quinolinyl;
- or
- Het is
- wherein R4 is H or C1-C6 alkyl;
- e is CR5;
- f is N;
- and R5 is H or NH2.
14 more elements
A compound which is:
- or a stereoisomer or pharmaceutically acceptable salt thereof.
A compound which is:
- or a stereoisomer or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.